Bioconjugated Antibody‐Trojan Immune Converter Enhance Cancer Immunotherapy with Minimized Toxicity by Programmed Two‐Step Immunomodulation of Myeloid Cells (Adv. Healthcare Mater. 27/2024)
Antibody-trojAn immune ConverterIn article 2401270 by Yong Taik Lim and co-worker, a programmed two-step activation strategy is suggested to enhance cancer immunotherapy with minimized systemic toxicities via Antibody-Trojan Immune Converter Conjugates that specifically targets myeloid cells by anti-SIRP followed by reactivation of transiently inactivated Trojan TLR7/8 agonist after antibody-mediated endocytosis.
Authors
- Suhyeon Kim (ORCID: https://orcid.org/0000-0001-8375-2491)
- JungHyub Hong
- Seung Mo Jin (ORCID: https://orcid.org/0000-0002-7379-4580)
- Yong‐Soo Bae (ORCID: https://orcid.org/0000-0002-2233-9449)
- J.H. Cho
- Yong Taik Lim (ORCID: https://orcid.org/0000-0001-5558-5526)
- Soyoung Park (ORCID: https://orcid.org/0000-0002-7647-1058)
Publication Details
- Journal
- Advanced Healthcare Materials
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/adhm.202470171
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00